

Eric Dannaoui

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3744510/eric-dannaoui-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

176
papers

9,128
citations

47
h-index

91
g-index

225
ext. papers

10,950
ext. citations

5.9
avg, IF

6.09
L-index

#	Paper	IF	Citations
176	Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes.. <i>Journal of Antimicrobial Chemotherapy</i> , 2022 ,	5.1	0
175	In Vitro Activity of Amphotericin B in Combination with Colistin against Fungi Responsible for Invasive Infections.. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022 , 8,	5.6	1
174	Extensive Dermatophytosis Caused by Terbinafine-Resistant Trichophyton indotineae, France.. <i>Emerging Infectious Diseases</i> , 2022 , 28, 229-233	10.2	1
173	Recent Developments in the Diagnosis of Mucormycosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022 , 8, 457	5.6	1
172	Synergy of Isavuconazole Combined With Colistin Against Common Species.. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022 , 12, 892893	5.9	0
171	Aspergillus detection in airways of ICU COVID-19 patients: To treat or not to treat?. <i>Journal De Mycologie Medicale</i> , 2022 , 32, 101290	3	0
170	Antifungal Drugs TDM: Trends and Update.. <i>Therapeutic Drug Monitoring</i> , 2021 , 44,	3.2	1
169	Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. <i>Lancet Respiratory Medicine</i> , 2021 ,	35.1	36
168	antifungal combination of terbinafine with itraconazole against isolates of spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , AAC0144921	5.9	0
167	Azole resistance in Aspergillus fumigatus isolates from respiratory specimens in Lyon University Hospitals, France: prevalence and mechanisms involved. <i>International Journal of Antimicrobial Agents</i> , 2021 , 58, 106447	14.3	1
166	Microsporidiosis after liver transplantation: A French nationwide retrospective study. <i>Transplant Infectious Disease</i> , 2021 , 23, e13665	2.7	1
165	A review of significance of Aspergillus detection in airways of ICU COVID-19 patients. <i>Mycoses</i> , 2021 , 64, 980-988	5.2	5
164	Analysis of Microbiota and Mycobiota in Fungal Ball Rhinosinuitis: Specific Interaction between and ?. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	2
163	Invasive Aspergillosis Due to Aspergillus Section Usti: A Multicenter Retrospective Study. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1379-1385	11.6	11
162	Scedosporiosis/lomentosporiosis observational study (SOS): Clinical significance of Scedosporium species identification. <i>Medical Mycology</i> , 2021 , 59, 486-497	3.9	8
161	as a screening tool to study virulence factors of. <i>Virulence</i> , 2021 , 12, 818-834	4.7	5
160	Species distribution and antifungal susceptibility of clinical isolates in Lebanon. <i>Future Microbiology</i> , 2021 , 16, 13-26	2.9	2

159	Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	11
158	Epidemiological and clinical study of microsporidiosis in French kidney transplant recipients from 2005 to 2019: TRANS-SPORE registry. <i>Transplant Infectious Disease</i> , 2021 , 23, e13708	2.7	2
157	Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0109321	5.9	1
156	In vitro synergy of isavuconazole in combination with colistin against <i>Candida auris</i> . <i>Scientific Reports</i> , 2020 , 10, 21448	4.9	13
155	and Show Different Trailing Effect Patterns When Exposed to Echinocandins and Azoles. <i>Frontiers in Microbiology</i> , 2020 , 11, 1286	5.7	2
154	Post-traumatic <i>Curvularia</i> sp. arthritis in an immunocompetent adult. <i>Journal De Mycologie Medicale</i> , 2020 , 30, 100967	3	1
153	for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review. <i>Microorganisms</i> , 2020 , 8,	4.9	22
152	Should Etest MICs for Yeasts Be Categorized by Reference (BPs/ECVs) or by Etest (ECVs) Cutoffs as Determinants of Emerging Resistance?. <i>Current Fungal Infection Reports</i> , 2020 , 14, 120-129	1.4	3
151	Colistin interacts synergistically with echinocandins against <i>Candida auris</i> . <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105901	14.3	21
150	Antifungal susceptibility testing practices in mycology laboratories in France, 2018. <i>Journal De Mycologie Medicale</i> , 2020 , 30, 100970	3	2
149	MixInYeast: A Multicenter Study on Mixed Yeast Infections. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 7,	5.6	6
148	In vitro synergy of echinocandins with triazoles against fluconazole-resistant <i>Candida parapsilosis</i> complex isolates. <i>Journal of Global Antimicrobial Resistance</i> , 2020 , 21, 331-334	3.4	1
147	Pneumocystis Infection Outbreaks in Organ Transplantation Units in France: A Nation-Wide Survey. <i>Clinical Infectious Diseases</i> , 2020 , 70, 2216-2220	11.6	13
146	In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against Species. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	7
145	Modulated Response of and to Antimicrobial Agents in Polymicrobial Biofilm. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 574028	5.9	6
144	Colistin and Isavuconazole Interact Synergistically In Vitro against and. <i>Microorganisms</i> , 2020 , 8,	4.9	4
143	Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1807-1819	5.1	16
142	Comparison of the MICs Obtained by Gradient Concentration Strip and EUCAST Methods for Four Azole Drugs and Amphotericin B against Azole-Susceptible and -Resistant Section Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	2

141	Antifungal combinations in Mucorales: A microbiological perspective. <i>Mycoses</i> , 2019 , 62, 746-760	5.2	16
140	In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1921-1927	5.1	12
139	Multicentre study to determine the Etest epidemiological cut-off values of antifungal drugs in <i>Candida</i> spp. and <i>Aspergillus fumigatus</i> species complex. <i>Clinical Microbiology and Infection</i> , 2019 , 25, 1546-1552	9.5	13
138	Identification of Mucorales by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019 , 5,	5.6	8
137	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases, The</i> , 2019 , 19, e405-e421	25.5	441
136	Indifferent effect of nonsteroidal anti-inflammatory drugs (NSAIDs) combined with fluconazole against multidrug-resistant. <i>Current Medical Mycology</i> , 2019 , 5, 26-30	1.1	4
135	antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against shows no antagonism. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 ,	5.9	21
134	Antifungal Susceptibly Testing by Concentration Gradient Strip Etest Method for Fungal Isolates: A Review. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019 , 5,	5.6	13
133	Occurrence and species diversity of human-pathogenic Mucorales in commercial food-stuffs purchased in Paris area. <i>Medical Mycology</i> , 2019 , 57, 739-744	3.9	5
132	Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: Results from the international prospective study "MFIP". <i>Journal of Cystic Fibrosis</i> , 2019 , 18, 212-220	4.1	22
131	Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in and Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	37
130	Comparative virulence of <i>Candida auris</i> with <i>Candida haemulonii</i> , <i>Candida glabrata</i> and <i>Candida albicans</i> in a murine model. <i>Mycoses</i> , 2018 , 61, 377-382	5.2	65
129	Prosthetic Valve <i>Candida</i> spp. Endocarditis: New Insights Into Long-term Prognosis-The ESCAPE Study. <i>Clinical Infectious Diseases</i> , 2018 , 66, 825-832	11.6	23
128	Species Identification and Antifungal Susceptibility of <i>Aspergillus terreus</i> Species Complex Clinical Isolates from a French Multicenter Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	12
127	Posaconazole MIC Distributions for <i>Aspergillus fumigatus</i> Species Complex by Four Methods: Impact of Mutations on Estimation of Epidemiological Cutoff Values. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	18
126	Occurrence and species distribution of pathogenic Mucorales in unselected soil samples from France. <i>Medical Mycology</i> , 2018 , 56, 315-321	3.9	12
125	In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of <i>Aspergillus fumigatus</i> from different geographical regions. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 91, 266-268	2.9	6
124	Azole Resistance in <i>Aspergillus fumigatus</i> in Patients with Cystic Fibrosis: A Matter of Concern?. <i>Mycopathologia</i> , 2018 , 183, 151-160	2.9	29

123	Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant <i>Aspergillus</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	10
122	PCR-based detection of <i>Aspergillus fumigatus</i> and absence of azole resistance due to TR /L98H in a french multicenter cohort of 137 patients with fungal rhinosinusitis. <i>Mycoses</i> , 2018 , 61, 30-34	5.2	11
121	<i>Candida auris</i> : An emerging drug resistant yeast - A mini-review. <i>Journal De Mycologie Medicale</i> , 2018 , 28, 568-573	3	48
120	Human cryptosporidiosis in immunodeficient patients in France (2015-2017). <i>Experimental Parasitology</i> , 2018 , 192, 108-112	2.1	15
119	In vitro antifungal activity of amphotericin B and 11 comparators against <i>Aspergillus terreus</i> species complex. <i>Mycoses</i> , 2018 , 61, 134-142	5.2	19
118	Population Structure of <i>Candida parapsilosis</i> : No Genetic Difference Between French and Uruguayan Isolates Using Microsatellite Length Polymorphism. <i>Mycopathologia</i> , 2018 , 183, 381-390	2.9	5
117	Interactions of and in an Mixed Biofilm Model: Does the Strain Matter?. <i>Frontiers in Microbiology</i> , 2018 , 9, 2850	5.7	14
116	<i>Aspergillus pseudodeflectus</i> : a new human pathogen in liver transplant patients. <i>BMC Infectious Diseases</i> , 2018 , 18, 648	4	3
115	An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017 , 1046, 26-33	3.2	23
114	Clinical outcome of cystic fibrosis patients colonized by <i>Scedosporium</i> species following lung transplantation: A single-center 15-year experience. <i>Transplant Infectious Disease</i> , 2017 , 19, e12738	2.7	18
113	Predisposing factors and outcome of uncommon yeast species-related fungaemia based on an exhaustive surveillance programme (2002-14). <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1784-1793	5.1	33
112	Echinocandin Resistance in <i>Candida</i> Species Isolates from Liver Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	30
111	Interactions of Echinocandins with Triazoles against Multidrug-Resistant. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	55
110	Antifungal resistance in mucorales. <i>International Journal of Antimicrobial Agents</i> , 2017 , 50, 617-621	14.3	51
109	Molecular Diagnosis of Invasive Aspergillosis and Detection of Azole Resistance by a Newly Commercialized PCR Kit. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 3210-3218	9.7	44
108	Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in <i>Candida</i> spp. and <i>Aspergillus</i> spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	30
107	In Vitro Activities of Novel Azole Compounds ATTAF-1 and ATTAF-2 against Fluconazole-Susceptible and -Resistant Isolates of <i>Candida</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	17
106	Preferential expression of domain cassettes 4, 8 and 13 of <i>Plasmodium falciparum</i> erythrocyte membrane protein 1 in severe malaria imported in France. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 211.e1-211.e4	9.5	3

105	Fatal Pulmonary Mucormycosis due to <i>Rhizopus homothallicus</i> . <i>Mycopathologia</i> , 2017 , 182, 907-913	2.9	5
104	Multicenter Comparison of the Etest and EUCAST Methods for Antifungal Susceptibility Testing of <i>Candida</i> Isolates to Micafungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5088-91	5.9	10
103	Characteristics of <i>Aspergillus fumigatus</i> in Association with <i>Stenotrophomonas maltophilia</i> in an In Vitro Model of Mixed Biofilm. <i>PLoS ONE</i> , 2016 , 11, e0166325	3.7	20
102	Reducing hypoxia and inflammation during invasive pulmonary aspergillosis by targeting the Interleukin-1 receptor. <i>Scientific Reports</i> , 2016 , 6, 26490	4.9	25
101	Novel Taxa Associated with Human Fungal Black-Grain Mycetomas: <i>Emarellia grisea</i> gen. nov., sp. nov., and <i>Emarellia paragrisea</i> sp. nov. <i>Journal of Clinical Microbiology</i> , 2016 , 54, 1738-1745	9.7	24
100	In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of <i>Scedosporium</i> spp. <i>Journal of Medical Microbiology</i> , 2015 , 64, 309-311	3.2	23
99	Prospective multicenter international surveillance of azole resistance in <i>Aspergillus fumigatus</i> . <i>Emerging Infectious Diseases</i> , 2015 , 21, 1041-4	10.2	238
98	Molecular identification of fungi found on decomposed human bodies in forensic autopsy cases. <i>International Journal of Legal Medicine</i> , 2015 , 129, 785-91	3.1	12
97	Next-generation sequencing offers new insights into the resistance of <i>Candida</i> spp. to echinocandins and azoles. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2556-65	5.1	34
96	Prospective evaluation of azole resistance in <i>Aspergillus fumigatus</i> clinical isolates in France. <i>Medical Mycology</i> , 2015 , 53, 593-6	3.9	28
95	Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1745-50	5.9	73
94	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: <i>Fusarium</i> spp., <i>Scedosporium</i> spp. and others. <i>Clinical Microbiology and Infection</i> , 2014 , 20 Suppl 3, 27-46	9.5	291
93	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. <i>Clinical Microbiology and Infection</i> , 2014 , 20 Suppl 3, 47-75	9.5	207
92	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. <i>Clinical Microbiology and Infection</i> , 2014 , 20 Suppl 3, 5-26	9.5	413
91	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. <i>Clinical Microbiology and Infection</i> , 2014 , 20 Suppl 3, 76-98	9.5	324
90	<i>Acremonium sclerotigenum</i> - <i>Acremonium egyptiacum</i> : a multi-resistant fungal pathogen complicating the course of aplastic anaemia. <i>Clinical Microbiology and Infection</i> , 2014 , 20, O30-2	9.5	6
89	In vitro combination of voriconazole and miltefosine against clinically relevant molds. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 6996-8	5.9	22
88	Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). <i>Intensive Care Medicine</i> , 2014 , 40, 1303-12	14.5	223

87	Emergence of echinocandin-resistant <i>Candida</i> spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014 , 33, 1489-96	5.3	56
86	Mutations in the Cyp51A gene and susceptibility to itraconazole in <i>Aspergillus fumigatus</i> isolated from avian farms in France and China. <i>Poultry Science</i> , 2014 , 93, 12-5	3.9	15
85	Current Status of Diagnosis of Mucormycosis: Update on Molecular Methods. <i>Current Fungal Infection Reports</i> , 2014 , 8, 353-359	1.4	3
84	Résistance des <i>Candida</i> aux antifongiques : détection et mécanismes. <i>Revue Francophone Des Laboratoires</i> , 2013 , 2013, 71-77	0	0
83	Rapid emergence of echinocandin resistance during <i>Candida kefyr</i> fungemia treatment with caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2380-2	5.9	41
82	Interlaboratory variability of Caspofungin MICs for <i>Candida</i> spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5836-42	5.9	172
81	Estimating the burden of mucormycosis infections in France (2005-2007) through a capture-recapture method on laboratory and administrative data. <i>Revue D'épidémiologie Et De Santé Publique</i> , 2012 , 60, 383-7	0.6	16
80	Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008). <i>Clinical Microbiology and Infection</i> , 2012 , 18, E396-400	9.5	51
79	ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. <i>Bone Marrow Transplantation</i> , 2012 , 47, 1030-45	4.4	70
78	Healthcare-associated mucormycosis. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 1, S44-54	11.6	169
77	<i>Candida</i> spp. with acquired echinocandin resistance, France, 2004-2010. <i>Emerging Infectious Diseases</i> , 2012 , 18, 86-90	10.2	103
76	Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 66-75	9.7	103
75	A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 1, S35-43	11.6	283
74	In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant <i>Aspergillus</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4500-3	5.9	15
73	Pneumocystosis: a network survey in the Paris area 2003-2008. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011 , 30, 673-5	5.3	20
72	Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 532-8	5.9	245
71	Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy eras. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011 , 85, 934-41	3.2	34
70	Increased mortality in young candidemia patients associated with presence of a <i>Candida albicans</i> general-purpose genotype. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 3250-6	9.7	17

69	Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in <i>Candida</i> spp.: a case-control study in Paris, France. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 5358-61	5.9	37
68	Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories. <i>Clinical Microbiology and Infection</i> , 2010 , 16, 863-9	9.5	27
67	Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 2043-6	9.7	69
66	<i>Geosmithia argillacea</i> : an emerging pathogen in patients with cystic fibrosis. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 2381-6	9.7	60
65	Successful triple combination therapy of disseminated <i>absidia corymbifera</i> infection in an adolescent with osteosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2010 , 32, 131-3	1.2	16
64	Zygomycosis After Allogeneic Hematopoietic Stem Cell Transplantation: A French Multicenter Cohort Study (2003-2008). <i>Blood</i> , 2010 , 116, 1263-1263	2.2	
63	In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 3549-51	5.9	45
62	Sequence-based identification of <i>Aspergillus</i> , <i>fusarium</i> , and <i>mucorales</i> species in the clinical mycology laboratory: where are we and where should we go from here?. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 877-84	9.7	255
61	Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. <i>Emerging Infectious Diseases</i> , 2009 , 15, 1395-401	10.2	258
60	Molecular and phenotypic evaluation of <i>Lichtheimia corymbifera</i> (formerly <i>Absidia corymbifera</i>) complex isolates associated with human mucormycosis: rehabilitation of <i>L. ramosa</i> . <i>Journal of Clinical Microbiology</i> , 2009 , 47, 3862-70	9.7	66
59	Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. <i>Transplant Infectious Disease</i> , 2009 , 11, 211-9	2.7	45
58	Molecular tools for identification of Zygomycetes and the diagnosis of zygomycosis. <i>Clinical Microbiology and Infection</i> , 2009 , 15 Suppl 5, 66-70	9.5	58
57	Isolement d' <i>Exophiala dermatitidis</i> dans des prélèvements d'origine pulmonaire: propos de six patients. <i>Journal De Mycologie Medicale</i> , 2009 , 19, 34-39	3	2
56	Réseau pneumocystose francilien: bilan de cinq années de surveillance (2003-2007). <i>Journal De Mycologie Medicale</i> , 2009 , 19, 290-293	3	5
55	An increasing trend of cutaneous zygomycosis caused by <i>Mycocladius corymbifer</i> (formerly <i>Absidia corymbifera</i>): report of two cases and review of primary cutaneous <i>Mycocladius</i> infections. <i>Medical Mycology</i> , 2009 , 47, 532-8	3.9	21
54	EUCAST technical note on fluconazole. <i>Clinical Microbiology and Infection</i> , 2008 , 14, 193-5	9.5	80
53	EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. <i>Clinical Microbiology and Infection</i> , 2008 , 14, 398-405	9.5	348
52	EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. <i>Clinical Microbiology and Infection</i> , 2008 , 14, 982-4	9.5	282

51	EUCAST Technical Note on voriconazole. <i>Clinical Microbiology and Infection</i> , 2008 , 14, 985-7	9.5	47
50	Lack of evidence of endosymbiotic toxin-producing bacteria in clinical <i>Rhizopus</i> isolates. <i>Mycoses</i> , 2008 , 51, 266-9	5.2	24
49	Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 778-81	5.9	39
48	Associations antifongiques dans les candidoses et aspergilloses invasives. <i>Reanimation: Journal De La Societe De Reanimation De Langue Francaise</i> , 2008 , 17, 259-266		3
47	Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1585-6	5.9	28
46	Molecular diagnosis of <i>Saksenaea vasiformis</i> cutaneous infection after scorpion sting in an immunocompetent adolescent. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 3169-72	9.7	37
45	Detection of caspofungin resistance in <i>Candida</i> spp. by Etest. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 2389-92	9.7	30
44	Mutations in the <i>fkp1</i> gene in <i>Candida albicans</i> , <i>C. tropicalis</i> , and <i>C. krusei</i> correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 3092-8	5.9	107
43	<i>Saksenaea vasiformis</i> infection, French Guiana. <i>Emerging Infectious Diseases</i> , 2008 , 14, 342-4	10.2	17
42	Clonal population of flucytosine-resistant <i>Candida tropicalis</i> from blood cultures, Paris, France. <i>Emerging Infectious Diseases</i> , 2008 , 14, 557-65	10.2	35
41	Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). <i>Clinical Microbiology and Infection</i> , 2007 , 13, 1018-22	9.5	40
40	Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 383-5	5.9	35
39	In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 3378-80	5.9	20
38	Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. <i>PLoS Medicine</i> , 2007 , 4, e21	11.6	270
37	Acquired resistance to echinocandins in <i>Candida albicans</i> : case report and review. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 1076-83	5.1	123
36	Carbon assimilation profiles as a tool for identification of zygomycetes. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 1433-9	9.7	43
35	The Zygomycetes 2007 , 159-183		2
34	Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of <i>Cryptococcus neoformans</i> during disseminated murine cryptococcosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 113-20	5.9	52

33	Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 2464-70	5.9	84
32	Molecular identification of black-grain mycetoma agents. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 3517-23	9.7	77
31	Molecular identification of zygomycetes from culture and experimentally infected tissues. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 340-9	9.7	135
30	Pneumocystosis: survey and DHPS genotype analysis in 14 Parisian hospitals in 2003 and 2004. <i>Journal of Eukaryotic Microbiology</i> , 2006 , 53 Suppl 1, S106-7	3.6	5
29	SUCCESSFUL TREATMENT OF BLACK-GRAIN MYCETOMA WITH VORICONAZOLE. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006 , 75, 1106-1107	3.2	38
28	Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of <i>Aspergillus fumigatus</i> . <i>Journal of Medical Microbiology</i> , 2006 , 55, 1457-1459	3.2	19
27	Successful treatment of black-grain mycetoma with voriconazole. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006 , 75, 1106-7	3.2	11
26	Antifungal combinations. <i>Methods in Molecular Medicine</i> , 2005 , 118, 143-52		32
25	In vitro evaluation of double and triple combinations of antifungal drugs against <i>Aspergillus fumigatus</i> and <i>Aspergillus terreus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 970-8	5.9	85
24	Susceptibility testing of sequential isolates of <i>Aspergillus fumigatus</i> recovered from treated patients. <i>Journal of Medical Microbiology</i> , 2004 , 53, 129-134	3.2	34
23	In vitro susceptibilities of zygomycetes to conventional and new antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 45-52	5.1	246
22	Invasive infections due to <i>Apophysomyces elegans</i> . <i>Mayo Clinic Proceedings</i> , 2003 , 78, 252-3	6.4	6
21	In vitro interaction of flucytosine with conventional and new antifungals against <i>Cryptococcus neoformans</i> clinical isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 3361-4	5.9	33
20	Activity of posaconazole in treatment of experimental disseminated zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 3647-50	5.9	141
19	Evaluation of different commercial ELISA methods for the serodiagnosis of systemic candidosis. <i>Mycoses</i> , 2002 , 45, 455-60	5.2	21
18	In vitro synergistic interaction between amphotericin B and pentamidine against <i>Scedosporium prolificans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 3323-6	5.9	38
17	In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 2708-11	5.9	69
16	Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 1953-9	5.9	47

15	In vitro susceptibilities of Zygomycota to polyenes. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 49, 741-4	5.1	16
14	Effect of medium composition on static and cidal activity of amphotericin B, itraconazole, voriconazole, posaconazole and terbinafine against <i>Aspergillus fumigatus</i> : a multicenter study. <i>Journal of Chemotherapy</i> , 2002 , 14, 246-52	2.3	5
13	Acquired itraconazole resistance in <i>Aspergillus fumigatus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2001 , 47, 333-40	5.1	117
12	Sterol composition of itraconazole-resistant and itraconazole-susceptible isolates of <i>Aspergillus fumigatus</i> . <i>Canadian Journal of Microbiology</i> , 2001 , 47, 706-710	3.2	7
11	Amphotericin B resistance of <i>Aspergillus terreus</i> in a murine model of disseminated aspergillosis. <i>Journal of Medical Microbiology</i> , 2000 , 49, 601-606	3.2	49
10	In-vivo itraconazole resistance of <i>Aspergillus fumigatus</i> in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of <i>Aspergillus fumigatus</i> . <i>Journal of Medical Microbiology</i> , 1999 , 48, 1087-1093	3.2	42
9	Early <i>Microascus cinereus</i> endocarditis of a prosthetic valve implanted after <i>Staphylococcus aureus</i> endocarditis of the native valve. <i>Clinical Infectious Diseases</i> , 1999 , 29, 691-2	11.6	14
8	In-vitro susceptibility of <i>Aspergillus</i> spp. isolates to amphotericin B and itraconazole. <i>Journal of Antimicrobial Chemotherapy</i> , 1999 , 44, 553-5	5.1	63
7	Use of spectrophotometric reading for in vitro antifungal susceptibility testing of <i>Aspergillus</i> spp.. <i>Canadian Journal of Microbiology</i> , 1999 , 45, 871-874	3.2	13
6	Detection of <i>Pneumocystis carinii</i> DNA by PCR amplification in various rat organs in experimental pneumocystosis. <i>Journal of Medical Microbiology</i> , 1997 , 46, 665-8	3.2	10
5	Inhibitory Effect of Penciclovir-Triphosphate on Duck Hepatitis B Virus Reverse Transcription. <i>Antiviral Chemistry and Chemotherapy</i> , 1997 , 8, 38-46	3.5	30
4	Fluconazole susceptibility of <i>Candida</i> isolates from oropharyngeal candidosis. <i>Mycoses</i> , 1997 , 40, 279-82	5.2	6
3	Evaluation of the E test for fluconazole susceptibility testing of <i>Candida albicans</i> isolates from oropharyngeal candidiasis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1997 , 16, 228-32	5.3	17
2	2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 1996 , 40, 448-53	5.9	42
1	Animal Models for Evaluation of Antifungal Efficacy Against Filamentous Fungi	115-135	